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INTRODUCTION
The impact and benefit of screening
and early detection of melanoma in the
general population is controversial.
Discrepancies exist in recommendations
across different organizations worldwide.
In the United States, a broad range of
screening and surveillance strategies
can be identified. The 2009 US Pre-
ventive Services Task Force stated that
because of limited evidence linking
skin cancer screening to improved health
outcomes, screening in the general
primary care population could not be
recommended (Wolff et al., 2009). This
statement was predicated on the lack of
evidence from randomized controlled
studies addressing the survival benefit
of screening for skin cancer based on
whole-body examination. Herein we
review the current data on alternative,
non-survival outcomes and benefits,
including reduction of melanoma thick-
ness at the time of diagnosis, reduced
morbidity, enhanced primary and sec-
ondary prevention education, increased
cost-effectiveness, and improved target-
ing of highest-risk populations, followed
by methods to improve the effectiveness
of screening. However, melanoma screen-
ing also comes with a price, which is
not limited to financial implications.
Some of the limitations challenging the
effectiveness of screening efforts include
potential ‘‘overdiagnosis’’, the difficulty
of early identification of rapidly devel-
oping melanomas, and the challenge of
reaching out to certain high-risk groups,
such as older males.
WHY HAS A SURVIVAL BENEFIT
NOT BEEN DEMONSTRATED?
Physician detection of melanomas
through routine physician examination
or opportunistic screening is asso-
ciated with thinner melanoma detec-
tion compared with patient detection
(Geller et al., 2009a). However,
whether this translates into improved
melanoma survival remains unclear.
The lack of a definitive survival ad-
vantage is largely based on the ab-
sence of randomized epidemiological
studies with sufficient power and long-
term follow-up. The challenge for
these studies is the large number of
cases required owing to the relatively
low incidence of melanoma, the ex-
tended time interval between diagno-
sis and disease recurrence, and the
relatively low mortality associated
with early lesions. Therefore, random-
ized controlled studies for melanoma
screening are costly (Geller et al.,
2009b). In the current economic cli-
mate where the cost of medical care
continues to escalate, especially in
treatment-related interventions, the
potential savings from prevention
and early detection programs needs
to be seriously considered, and is likely
worth the research funding invest-
ment.
Research trials have shown supportive
evidence on the value of screening
Attempts to carry out formal studies of
melanoma screening have been under-
taken, including a community-based
trial in Queensland, a pilot study
of general population screening in
Germany, The Lawrence Livermore
National Laboratory (LLNL) screen-
ing program, and a retrospective anal-
ysis of surveillance epidemiology and
end results data in the United States,
among others. The Australian clinical
trial was designed to detect 20%
reduction in mortality from melanoma
during the 15-year intervention period
(Aitken et al., 2002). The proposed
sample included 44 eligible Queens-
land communities (aggregate popula-
tion of 560,000 adults aged 30 years
or more) randomized into intervention
or control groups to undergo a
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community-based melanoma screening
program for 3 years versus usual medical
care. Owing to the associated cost, the
clinical trial could not be completed
(From et al., 2007). However, impor-
tant lessons have been learned from the
18 towns enrolled and randomized in
the study. Within intervention commu-
nities, the prevalence of clinical skin
examinations in two of the intervention
groups reported significantly higher
prevalence of clinical examinations
(16.5 and 27.1%) than the control
group (10.9%, Po0.001; Janda et al.,
2006). In addition, the overall rate of
skin cancer detected per 100 patients
screened was increased, and men and
attendees older than 50 years more
frequently received a referral and diag-
nosis of melanoma. Of those melano-
mas found through the screening
program, about 39% were in situ
lesions, 55% were thin invasive lesions
less than 1mm thick, and 6% were
1mm thick or greater. Within the
population of Queensland during the
period from 1999 to 2002, the corre-
sponding percentages were as follows:
36%, in situ melanomas; 48%, invasive
melanomas less than 1mm thick; and
16%, invasive melanomas 1mm thick
or more, indicating that melanomas
found through screening tend to be less
advanced than those detected sympto-
matically. The specificity for detection
of melanoma through whole-body skin
examination by a primary care physi-
cian was comparable to that of other
screening tests, including mammogra-
phy (Aitken et al., 2006).
A screening program conducted by
the LLNL between 1984 and 1996
involving melanoma education, self-
examination, and opportunity for phy-
sician-based skin screening resulted in
a reduction in crude incidence of thicker
melanomas (from 22 to 4.6 per 100,000
person years). A reduction in mortality
was estimated based on data from the
California melanoma mortality data
over the same time period. No eligible
melanoma deaths occurred among
LLNL employees during the screening
period, whereas the expected number
of deaths was calculated to be 3.39
deaths (P¼0.034; Schneider et al.,
2008). Although the mortality analysis
proposed in the study is subjected to
some limitations, including demographic
differences between the two popula-
tions, the reduction in crude incidence
in melanomas thicker than 0.75mm
represents the most convincing outcome
of this study and a significant contribu-
tion to the effectiveness of melanoma
screening.
A US retrospective study by Pennie
et al., 2007 showed that tumor detection
by a dermatologist versus non-derma-
tologist was associated with earlier
stage and thinner tumors with potential
implication of a significant survival
benefit. Specifically, their analysis of
surveillance epidemiology and end
results data from 1991 to 1996 showed
that noncancer-related mortality was
similar for the melanoma patients
diagnosed by dermatologists versus
non-dermatologists, but the patients
whose tumors were detected by
dermatologists had lower cancer-
related mortality (13 vs. 21%; Po0.01)
and overall mortality (29 vs. 37%;
Po0.01). Multivariate analysis showed
that age, sex, stage at diagnosis, and
melanoma detection by a dermatolo-
gist were all significantly predictive
of survival.
In Schleswig-Holstein, a pilot study
demonstrated that the percentage of early
stage I disease increased from 52% in
the prescreening period (7/2001–6/
2003) to 64% in the actual screening
period (7/2003–6/2004) following a large-
scale multimedia campaigns (Katalinic
et al., 2003). On the basis of the
identification of an increased number
of thinner tumors associated with this
pilot study, the German Federal Joint
Committee established the inclusion of
skin cancer screenings as part of the
services provided by the Health Insur-
ance Funds. The Federal Joint Commit-
tee will evaluate the success of skin
cancer screening and will introduce
any necessary changes to the program
(Geller et al., 2010). Since July 2008,
complete whole-body screenings
are being offered free of charge once
every 2 years for all 45 million
German residents aged 35 years and
above. Although this massive endea-
vor is not a randomized clinical trial,
it can be anticipated that the result-
ing voluminous data on incidence,
morbidity, mortality, and burden of
disease will be highly informative. To
date, more than 10 million examina-
tions have taken place, and the goal of
training the nation’s 45,000 physicians
with an 8-hour training program has
been nearly reached (Geller et al.,
2010).
Taken together, these studies de-
monstrate the utility of tumor depth as
a target measure of successful screening
intervention. Furthermore, the LLNL
and US retrospective study by Pennie
suggests a beneficial effect on mortality
despite the lack of direct survival end
points.
ADDITIONAL BENEFITS TO
MELANOMA SCREENING
Surveillance offers a number of benefits
beyond a potential survival advantage
that may also improve patient care.
These include the opportunity to
decrease morbidity by diagnosing
patients with early-stage disease,
increased education/prevention, reduced
costs, and the identification of family
members at increased risk to develop
melanoma.
Surveillance decreases morbidity in
patients diagnosed with early-stage disease
The identification of thinner melano-
mas has the potential to minimize the
morbidity associated with surgical
procedures. Specifically, the NCCN
recommends a 5-mm margin and ex-
tension into the subcutaneous fat for
the re-excision of melanoma in situ,
whereas 1–2 cm and deep margins
extending to the muscular fascia are
recommended for thicker tumors (Coit
et al., 2009). The difference in surgical
margins can have significant conse-
quences for the patient depending on
the location of the melanoma and
associated comorbidities. An additional
level of morbidity associated with
thicker lesions includes the sentinel
lymph node biopsy (SLNB) for patho-
logical staging of the regional lymph
nodes. Patients with a positive SLNB
result are often also subjected to the
significant morbidity of a complete
lymph node dissection, which high-
lights the relevance of identifying thin
melanomas. Early melanoma detec-
tion will also lead to decreased risk
for distant metastasis and therefore
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decreased morbidity associated with
further surgical and medical interven-
tions.
Screening allows for increased
education/prevention
Perhaps one of the most powerful and
least quantifiable benefits associated
with melanoma screening relates to
the opportunity to educate patients
with respect to skin cancer risk factors
and primary and secondary preven-
tion methods. These encounters with
patients at risk of melanoma provide an
important opportunity for patient edu-
cation and dissemination of effective
information.
Surveillance also allows for anxiety
management, a benefit that has been
primarily evaluated in the setting of
patients diagnosed with melanoma
(Kasparian et al., 2009).
The capacity of achieving an early
stage of diagnosis through education
and simple visual inspection either by
the patient or a health-care provider is
a unique aspect of melanoma and other
skin cancers. This is in comparison
with other cancers such as colon,
prostate, or lung where more invasive
screening methods are necessary to
achieve effective secondary prevention
interventions.
Several reports have demonstrated a
suboptimal level of skin cancer screen-
ing behavior even in patients at high
risk of developing melanoma (Geller
et al., 2003; Robinson et al., 2007;
Kasparian et al., 2010). Factors such as
doctor recommendation, self-efficacy/
confidence in the ability to effectively
perform skin self-examination (SSE),
positive beliefs about melanoma
treatment and intention to perform
SSE in the future, comfort with
having a partner help with SSE,
perceived melanoma/skin cancer
risk, concern about developing skin
cancer/skin damage, and melanoma/
skin cancer knowledge have demon-
strated to be relevant variables
driving the effectiveness of SSE im-
plementation.
Therefore, there should be a con-
tinued attempt to directly or indirectly
evaluate the effect of education in
ongoing and future melanoma preven-
tion studies.
Is surveillance cost-effective?
Cost-effectiveness analysis is a useful
indicator of the value of screening
methods when decisions are being
made in the absence of randomized
trials with mortality end points, and
when the best-available data can be
combined from numerous sources to
inform policy. Such analyses have been
used to guide clinical decision making
in colon cancer screening, breast can-
cer screening, and human immuno-
deficiency virus disease management
(Weinstein et al., 2001; Mandelblatt
et al., 2003; Losina et al., 2007). As
mentioned above, this approach will
also be valid in melanoma where there
is every reason to believe that decreased
mortality can be achieved through early
detection, despite the absence of random-
ized controlled studies. The quality-
adjusted life year (QALY) is a measure
of disease burden, including both the
quality and the quantity of life lived.
Using this methodology, interventions in
the United States are generally consid-
ered cost-effective at less than $50,000
per QALY gained or less than $100,000
per QALY gained (Ubel et al., 2003;
Goldman, 2005). The cost-effectiveness
of melanoma surveillance has been
evaluated from multiple perspectives
including the impact of melanoma
screening with respect to years of life
saved (YLS), the financial implications of
early detection, and the role of long-term
surveillance and testing of patients diag-
nosed with early-stage melanoma.
Several studies have estimated the
cost-effectiveness of melanoma screen-
ing (Girgis et al., 1996; Youl et al.,
2007). Freedberg estimated a cost-
effectiveness ratio of $39,600 per YLS
for one-time screening in a population
at high risk (Freedberg et al., 1999).
This study was limited to one-time
screening, was applied in a younger
population, and did not account for
increased progression and recurrence
of melanoma. Beddingfield (2003)
estimated a cost-effectiveness ratio of
$220,700 per YLS for one-time screen-
ing of a white population of all ages at
average risk. However, the cost-effec-
tiveness for older patients was much
lower at $28,700 per YLS. The study by
Losina used a computer simulation to
evaluate four alternative melanoma
screening strategies: background screen-
ing only, and screening once, every 2
years, and annually, all beginning at the
age of 50 years. Their study demon-
strated a 1.6 QALYs per 1,000 persons
for one-time melanoma screening of the
general population older than 50 years
and a cost-effectiveness ratio of US
dollars 10,100 per QALY, a very cost-
effective value compared with other
cancer screening programs in the United
States. In addition, screening every 2 years
in siblings of patients with melanoma
(relative risk, 2.24 compared with the
general population) was also cost-
effective with a 9.8 QALY per 1,000
people screened and associated cost-
effectiveness ratio of US dollars 35,500
per QALY (Losina et al 2007). The
discrepancies in the cost-effectiveness
observed in older patients between the
Beddingfield and the Losina studies
were explained by differences in defin-
ing the higher-risk population and
screening cost. However, the policy
recommendations were similar.
An additional perspective with re-
spect to cost-effectiveness of melano-
ma relates to the impact on stage of
disease at diagnosis and its conse-
quences with respect to morbidity and
financial cost. Specifically, Alexandrescu
(2009) demonstrated a marked incre-
mental total cost associated with pro-
gressively higher initial stages of the
disease, ranging from a total of $4,648.48
for in situ tumors to $159,808.17 for
stage IV melanoma.
An additional cost associated with
the diagnosis of thicker primary tumors
includes the indication for SLNB. Patient
charges for SLNB have been reported to
range from $10,096 to $15,223 US
dollars, compared with $1,000 to $1,740
US dollars for outpatient-wide local exci-
sion (WLE) alone (Agnese et al., 2003).
Surveillance allows for identification of
family members at increased risk to develop
melanoma
Screening of patients at risk of devel-
oping melanoma based on nevi/skin
phenotype or family history fosters
promotion of effective primary and
secondary prevention strategies (Albert
et al., 1990; Brady et al., 2000). Ulti-
mately, information dissemination and
adoption of effective and consistent
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skin surveillance techniques has the
potential to result in early detection of
melanomas and decrease the morbidity
associated with later stages of diagno-
sis.
TARGETED AND COMPREHENSIVE
SURVEILLANCE IS AN OPPORTU-
NITY TO IMPROVE THE EFFECTIVE-
NESS OF MELANOMA SCREENING
A number of studies support the notion
that identification of individuals at
increased risk of melanoma is impor-
tant as targeted surveillance has dem-
onstrated an increased sensitivity and
specificity in diagnosis (Feit et al.,
2004; Wang et al., 2004; Banky et al.,
2005; Rademaker and Oakley, 2010).
However, a significant variability with
respect to skin cancer screening prac-
tices targeting high-risk patients has
been described in dermatology-based
practices (Federman et al., 2002). To
facilitate the identification of high-risk
populations to intervene with more
comprehensive and longitudinal sur-
veillance strategies, a series of popula-
tion-specific risk assessment tools have
been designed to increase the objectiv-
ity of the selection process (Cho et al.,
2005; Fortes et al., 2010; Mar et al.,
2011). The vast majority of these
tools share a similar configuration
with respect to the type of risk factors
included in the model (e.g., personal
and family history of melanoma,
number of common and atypical
nevi, history of sunburns, hair color,
and freckling). However, the consis-
tent adoption and implementation of
these tools into daily practice re-
quires further improvement.
When evaluating methods to im-
prove the value of screening, the
implementation of imaging techniques
such as dermoscopy and photographic
documentation at the single lesion,
regional, and total body level (TBP)
should be given particular considera-
tion. The added value of this compre-
hensive approach in the evaluation of
high-risk melanoma patients has been
documented in both the community
dermatology setting (Wang et al., 2004;
Rademaker and Oakley, 2010) and
particularly in the case of specialized
Pigmented Lesion Clinics (Feit et al.,
2004; Banky et al., 2005).
Melanoma detection remains the
most important indication of dermo-
scopy, and in melanoma screening the
aim of dermoscopy is to maximize
early detection while minimizing the
unnecessary excision of benign skin
tumors. Specifically, the implementa-
tion of dermoscopy in the evaluation of
pigmented skin lesion evaluation has
demonstrated a benign/malignant ratio
improvement from 18:1 to 4.3:1
(P¼0.037; Carli et al., 2004). In the
past few years, three meta-analyses and
two randomized studies have definitely
proven that dermoscopy improves the
sensitivity for melanoma diagnosis as
compared with the naked-eye exam-
ination alone.
In the case of TBP, a study by Feit
had follow up on 576 patients with 93
biopsied lesions. Twenty-seven (35%)
of 77 melanocytic lesions were histo-
logically diagnosed as melanoma (Feit
et al., 2004). In a study by Banky using
TBP, the benign-to-malignant ratio was
also approximately 3:1 (Banky et al.,
2005). These ratios compare very fa-
vorably with the ratios of 12:1 or 30:1
reported for dermatologists not imple-
menting the use of TBP and general
physicians, respectively (Banky et al.,
2005). Although benign/malignant ratio
of biopsies is a useful indicator of
diagnostic accuracy, the patient mix
seen by each individual physician can
modify the outcome of this parameter.
In addition to improvement on benign/
malignant ratio of biopsies, the mel-
anomas detected using photographic
aid tend to be thinner. In the Banky
study, 44% of melanomas were in
situ, and the median thickness of the
invasive tumors was 0.39mm. In
comparison, 35% of melanomas in
the region were in situ and the
median thickness of the invasive
tumors was 0.60mm.
Although the above studies were
primarily conducted in settings en-
riched for patients at high risk of
developing melanoma in community
dermatology practices and Pigmented
Lesion Clinics, their comprehensive
approach can help disseminate diag-
nostic methodologies that are more
effective in identifying early melanomas.
Ultimately, the most efficient approach
for melanoma detection may involve a
tiered system, with the patients at highest
risk receiving the most intensive sur-
veillance.
WHAT ARE THE LIMITATIONS OF
THE CURRENT EVIDENCE SUPPORTING
THE IMPLEMENTATION OF MELA-
NOMA SCREENING?
Important considerations when eval-
uating the outcome of the clinical
studies evaluating the effect of mela-
noma surveillance include the differ-
ence in the study design, demographic
variability, the bias introduced by
‘‘overdiagnosis’’ of thin melanomas,
and the importance of identifying a
decrease in the population-based in-
cidence of deeply invasive disease as
a target measure of successful inter-
vention.
In the case of cost-effectiveness
studies, major limitations for these
analyses include the fact that they are
based upon models that incorporate
assumptions believed to be relevant by
a certain group of investigators con-
ducting the studies. In addition, the studies
evaluating the cost-effectiveness of
screening intervention do not account
for the potential effect of ‘‘overdiagnosis’’
in their models. Despite this limitation
and irrespective of the difference in
health-care systems and financial cost
associated with the surgical manage-
ment of melanoma, a significant savings
could be generated from minimizing
the number of cases undergoing SLNB
for staging purposes.
Melanoma ‘‘overdiagnosis’’ and ‘‘diagnostic
drift’’
An important consideration when as-
sessing the effectiveness of screening
methods and reported incidence of
melanoma relates to the controversial
topics of (a) ‘‘overdiagnosis’’ resulting
from detection pressure, leading to the
identification of early melanomas that are
biologically not destined to progress
into invasive and/or metastatic disease,
and (b) ‘‘diagnostic drift’’ as a conse-
quence of increased sensitivity for the
pathological diagnosis of melanoma
when evaluating atypical melanocytic
lesions, particularly in the case of mela-
nomas in situ (Welch and Black, 2010).
Several studies have raised the con-
cern of an error amplification effect
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generated by the above-mentioned
phenomena through melanoma screen-
ing (Welch et al., 2005; Shuster, 2009;
Torres-Cabala et al., 2010; Welch and
Black, 2010). Through this process, the
histopathological reclassification of
benign disease as malignant results in
a situation where overdiagnosis of
malignancy could outweigh underdiag-
nosis. The error would then be ampli-
fied through patient screening. Some of
the factors that make melanoma screen-
ing particularly susceptible to a ‘‘diag-
nostic drift’’ include the limited rate of
histological agreement between pathol-
ogists when evaluating borderline mel-
anocytic lesions (Farmer et al., 1996;
Shoo et al., 2010), and the potential
effect of medical liability associated
with misdiagnosis (High, 2008). An
additional consideration when asses-
sing a drift in diagnosis include the
contribution of molecular diagnostic
tools to determine whether an atypical
melanocytic lesion represents melano-
ma (Braun-Falco et al., 2009). To what
extent the increase in melanoma in-
cidence rate truly represents new mela-
nomas possibly due to larger exposure to
associated risk factors, such as UV
exposure, and is not just a result of
‘‘overdiagnosis’’ or ‘‘diagnostic drift’’ still
needs to be properly investigated (Linos
et al., 2009). Overall, the continued rise
in melanoma mortality rates suggest that
at least a portion of the increased
incidence in melanoma is a real phe-
nomenon and not just an artifact due to
‘‘overdiagnosis’’ (ACS Cancer Facts
and Figures, 2011).
Melanomas not as amenable to early
detection
The accurate diagnosis of melanoma is
challenged by a group of melanoma
subtypes that significantly contribute to
melanoma mortality and are likely to
be missed as they are not as amenable
to early detection strategies. This group
of lesions includes nodular melanomas
(accounting for B40% of newly diag-
nosed thick (42mm) tumors (Geller
et al., 2009) and 46% of ultimately fatal
melanoma (Shaikh et al., 2011), des-
moplastic melanomas (Feng et al., 2011),
and amelanotic melanomas (2–8% of
all melanomas (Menzies et al., 2008)).
In addition, it is unclear what percen-
tage of cases presenting as metastatic
melanoma of unknown primary (3.2%
of melanomas) represent cases that had
pre-existing primary lesions that would
have been amenable to early detection
(Kamposioras et al., 2010). Melanomas
arising in mucosal sites and other less
favorable sites for early detection also
contribute to the mortality rates
(McLaughlin et al., 2005). Although
these types of melanoma represent a
small proportion of melanomas overall,
the survival benefit of melanoma screen-
ing might be inherently limited by the
incidence of these types of tumors.
Older males
Another challenge to the effective testing
and implementation of melanoma screen-
ing is the documented resistance to
screening evaluations and self skin
examinations by men of ageX50 years
(Swetter et al., 2004; Geller et al.,
2006a, b; Geller et al., 2009). Despite
recent trends showing improved survi-
val, and stabilization of incidence rates
in younger Americans, melanoma in-
cidence and mortality continue to rise
steadily in older individuals, particularly
in men above the age of 65 years (Geller
et al., 2003). A similar trend in this
demographic group has been observed
in Australia (Chamberlain et al., 2002)
and Germany (Buettner et al., 2005).
CONCLUSION
Although it is likely that melanoma
surveillance will ultimately prove a
survival benefit, the value of medical
care is not simply based on reduction
of mortality. There are numerous po-
tential benefits to be considered when
making policy regarding the value of
melanoma screening. On the other
hand, the expense and morbidity asso-
ciated with over-biopsy, misdiagnosis,
overdiagnosis, and those patients des-
tined to succumb to melanoma despite
intervention, must be factored into the
equation. Therefore, recommendations
for melanoma surveillance in the gen-
eral population must carefully weigh
these costs and benefits. Ultimately, a
rational approach to melanoma surveil-
lance through educational efforts to
the public, effective education of health-
care providers to increase diagnostic
accuracy, and screening and referral
patterns according to risk factor stra-
tification will lead to a more balanced
intervention while reducing the mor-
tality associated with the disease.
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